IDEXX LABORATORIES INC /DE IDXX

IDEXX Laboratories, the veterinary and livestock diagnostics giant, last filed its quarterly accounts on 5 May 2026 and revealed that it generated $1.14 billion of revenue in the three months to 31 March 2026, booked $278.4 million of net income, and produced $266.2 million of operating cash. The balance sheet at 31 March 2026 showed $3.39 billion of assets, $1.83 billion of liabilities, and $1.56 billion of shareholders’ equity. Cash and equivalents stood at $200.5 million, down from earlier quarters, and inventory sat at $382.4 million, a figure that fell by $2.2 million in the period. Research and development spend was $65.8 million, and capital expenditure was $32 million. Diluted earnings per share were $3.47 on 80.2 million diluted shares (source: IDEXX 10-Q, period ending 2026-03-31, https://www.sec.gov/Archives/edgar/data/874716/000087471626000076/idxx-20260331.htm).

Behind the headline numbers sits a business model built on multi-year contracts that bundle hardware, consumables, and cloud services, with IDEXX Points thrown in to keep customers loyal and the revenue curve smooth. The company disclosed $312.7 million of contract assets at 31 December 2025, of which $20.6 million moved off the balance sheet and into accounts receivable when customers were billed during Q1 2026. The company also disclosed that it grants IDEXX Points as customer incentives for signing multi-year minimum purchase deals, a practice that recognises revenue over time while the cash and points obligations sit in the accounting basement (source: IDEXX 10-Q, period ending 2026-03-31, https://www.sec.gov/Archives/edgar/data/874716/000087471626000076/idxx-20260331.htm).

The filings are a reminder that IDEXX is not merely selling test tubes; it is selling a recurring revenue platform that turns every sheep sample, every pet blood draw, and every dairy tanker sample into a data point that pays rent. The $382.4 million of inventory-chemical reagents, cartridges, and disposables-is the physical manifestation of that platform, while the $65.8 million of R&D and $32 million of capex are the bets that tomorrow’s diagnostics kit will fit the same recurring-revenue handshake. The company’s latest 8-K and Forms 4, SD, and 144 add colour without changing the core story: a diagnostics powerhouse whose revenue and cash are locked in the short run by contracts and in the long run by the reliability of its machines and the loyalty of its vet and farm customers (source: IDEXX 10-Q, period ending 2026-03-31, https://www.sec.gov/Archives/edgar/data/874716/000087471626000076/idxx-20260331.htm; IDEXX 8-K, 2026-05-05, https://www.sec.gov/Archives/edgar/data/874716/000110465926055203/tm2613510d1_8k.htm; SEC EDGAR Form 4, 2026-06-02, https://www.sec.gov/Archives/edgar/data/874716/000087471626000114/xslF345X06/wk-form4_1780434004.xml; SEC EDGAR Form SD, 2026-06-01, https://www.sec.gov/Archives/edgar/data/874716/000087471626000112/formsd-2025.htm; SEC EDGAR Form 144, 2026-05-20, https://www.sec.gov/Archives/edgar/data/874716/000195824426000299/xsl144X01/primary_doc.xml).

Analysts and investors who want a window into the mechanics can watch the SEC submissions feed and the company-facts JSON for any shifts in contract assets, inventory turns, or R&D intensity. The SEC submissions JSON is the plumbing; the company-facts JSON is the dashboard. Neither is a crystal ball, but both are the closest the public gets to a live feed of the company’s muscle movements (source: SEC EDGAR submissions JSON, https://data.sec.gov/submissions/CIK0000874716.json; SEC EDGAR companyfacts JSON, https://data.sec.gov/api/xbrl/companyfacts/CIK0000874716.json).

For context on where the stock has traded of late, the market has been watching the same filings the company files, so the chart is best read as a proxy for disclosure flow rather than fundamental discovery. The TradingView chart rail will show the price action around the 5 May 2026 filing date and any subsequent Form 4 or Form SD dates; the source directs readers to treat those moves as reactions to disclosure, not as a verdict on the business. The absence of earnings-guidance updates in the filings means the market is left to model the contract-to-cash conversion and the R&D payoff for itself (source: SEC EDGAR filing index, https://www.sec.gov/edgar/browse/?CIK=874716).

The story that still needs filling is the geographic breakdown of the $1.14 billion revenue. The 10-Q does not separate the US from OUS segments, so we do not know whether the next leg of growth is coming from export vet labs or from American backyard breeders upgrading to IDEXX analysers. Until the company discloses segment splits or provides commentary on regional demand, the revenue engine remains a black box behind the contract assets. A regional split in the next 10-Q would sharpen the picture (source: IDEXX 10-Q, period ending 2026-03-31, https://www.sec.gov/Archives/edgar/data/874716/000087471626000076/idxx-20260331.htm).